Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M-V, Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302–12. https://doi.org/10.1016/s1470-2045(19)30309-2.

Article  PubMed  Google Scholar 

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48. https://doi.org/10.1016/s1470-2045(14)70442-5.

Article  PubMed  Google Scholar 

Mi J-Q, Zhao W, Jing H, Fu W, Hu J, Chen L, et al. Phase II, Open-Label study of ciltacabtagene autoleucel, an Anti–B-Cell maturation antigen chimeric antigen Receptor–T-Cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2023;41:1275–84. https://doi.org/10.1200/jco.22.00690.

Article  CAS  PubMed  Google Scholar 

Goldfinger M, Shah N, Cooper DL. Chimeric antigen receptor T-Cell therapy for patients with multiple Myeloma—A call for equal opportunity. JAMA Oncol. 2023;9:297–8. https://doi.org/10.1001/jamaoncol.2022.6834.

Article  PubMed  Google Scholar 

Kazandjian D, Hill E, Dew A, Morrison C, Roswarski J, Korde N, et al. Carfilzomib, Lenalidomide, and dexamethasone followed by Lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with High-risk smoldering myeloma: A phase 2 nonrandomized controlled trial. JAMA Oncol. 2021;7:1678–85. https://doi.org/10.1001/jamaoncol.2021.3971.

Article  PubMed  Google Scholar 

Landgren O, Hultcrantz M, Diamond B, Lesokhin AM, Mailankody S, Hassoun H, et al. Safety and effectiveness of weekly Carfilzomib, Lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. 2021;7:862–8. https://doi.org/10.1001/jamaoncol.2021.0611.

Article  PubMed  PubMed Central  Google Scholar 

Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33. https://doi.org/10.4065/78.1.21

Drake MT. Bone disease in multiple myeloma. Oncol (Williston Park). 2009;23:28–32.

Google Scholar 

Baffour FI, Glazebrook KN, Kumar SK, Broski SM. Role of imaging in multiple myeloma. Am J Hematol. 2020;95:966–77. https://doi.org/10.1002/ajh.25846.

Article  PubMed  Google Scholar 

Jamet B, Morvan L, Nanni C, Michaud AV, Bailly C, Chauvie S, et al. Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials. Eur J Nucl Med Mol Imaging. 2021;48:1005–15. https://doi.org/10.1007/s00259-020-05049-6.

Article  CAS  PubMed  Google Scholar 

Lecouvet FE, Boyadzhiev D, Collette L, Berckmans M, Michoux N, Triqueneaux P, et al. MRI versus (18)F-FDG-PET/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance. Eur Radiol. 2020;30:1927–37. https://doi.org/10.1007/s00330-019-06469-1.

Article  PubMed  Google Scholar 

Bourillon C, Rahmouni A, Lin C, Belhadj K, Beaussart P, Vignaud A, et al. Intravoxel incoherent motion Diffusion-weighted imaging of multiple myeloma lesions: correlation with Whole-Body dynamic contrast Agent-enhanced MR imaging. Radiology. 2015;277:773–83. https://doi.org/10.1148/radiol.2015141728.

Article  PubMed  Google Scholar 

Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33:657–64. https://doi.org/10.1200/JCO.2014.57.9961.

Article  PubMed  Google Scholar 

Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of 18 F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group. Lancet Oncol. 2017;18:e206–17. https://doi.org/10.1016/s1470-2045(17)30189-4.

Article  PubMed  Google Scholar 

Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr., et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007;25:1121–8. https://doi.org/10.1200/JCO.2006.08.5803.

Article  PubMed  Google Scholar 

Gómez León N, Aguado Bueno B, Herreros Pérez M, León Ramírez LF, Alegre A, Colletti PM, et al. Agreement between 18F-FDG PET/CT and Whole-Body magnetic resonance compared with skeletal survey for initial staging and response at End-of-Treatment evaluation of patients with multiple myeloma. Clin Nucl Med. 2021;46:310–22. https://doi.org/10.1097/RLU.0000000000003512.

Article  PubMed  PubMed Central  Google Scholar 

Hill E, Mena E, Morrison C, Dew A, Choyke P, Lindenberg L, et al. Diagnostic performance of 18 F-FDG-PET/CT compared to standard skeletal survey for detecting bone destruction in smouldering multiple myeloma: time to move forward. Br J Haematol. 2021;193:125–8. https://doi.org/10.1111/bjh.17088.

Article  CAS  PubMed  Google Scholar 

Hillengass J, Landgren O. Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging early myeloma. Leuk Lymphoma. 2013;54:1355–63. https://doi.org/10.3109/10428194.2012.740559.

Article  PubMed  Google Scholar 

Mulé S, Reizine E, Blanc-Durand P, Baranes L, Zerbib P, Burns R, et al. Whole-Body functional MRI and PET/MRI in multiple myeloma. Cancers. 2020;12:3155. https://doi.org/10.3390/cancers12113155.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, et al. Standardization of (18)F-FDG-PET/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol. 2021;39:116–25. https://doi.org/10.1200/JCO.20.00386.

Article  CAS  PubMed  Google Scholar 

Han S, Woo S, Kim Y-I, Yoon DH, Ryu J-S. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis. Eur Radiol. 2021;31:152–62. https://doi.org/10.1007/s00330-020-07177-x.

Article  CAS  PubMed  Google Scholar 

Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, et al. Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2016;43:414–21. https://doi.org/10.1007/s00259-015-3200-9.

Article  CAS  PubMed  Google Scholar 

Nanni C. PET-FDG: impetus. Cancers. 2020;12:1030. https://doi.org/10.3390/cancers12041030.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, et al. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Eur J Nucl Med Mol Imaging. 2018;45:712–9. https://doi.org/10.1007/s00259-017-3909-8.

Article  PubMed  Google Scholar 

Sachpekidis C, Merz M, Raab M-S, Bertsch U, Weru V, Kopp-Schneider A, et al. The prognostic significance of [18F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs). EJNMMI Res. 2021;11:100. https://doi.org/10.1186/s13550-021-00846-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sachpekidis C, Hillengass J, Goldschmidt H, Mosebach J, Pan L, Schlemmer HP, et al. Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. Am J Nucl Med Mol Imaging. 2015;5:469–78. eCollection 2015.

PubMed  PubMed Central  Google Scholar 

Jamet B, Carlier T, Bailly C, Bodet-Milin C, Monnet A, Frampas E, et al. Hybrid simultaneous whole-body 2-[18F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results. Eur Radiol. 2023;33:6438–47. https://doi.org/10.1007/s00330-023-09593-1.

Article  CAS  PubMed  Google Scholar 

Burns R, Mulé S, Blanc-Durand P, Tofighi M, Belhadj K, Zerbib P, et al. Optimization of whole-body 2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma. Eur Radiol. 2022;32:3085–96. https://doi.org/10.1007/s00330-021-08388-6.

Article  CAS  PubMed  Google Scholar 

Moreau P, Attal M, Caillot D, Macro M, Karlin L, et al. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-Computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2911–8. https://doi.org/10.1200/JCO.2017.72.2975.

Article  CAS  PubMed